• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Stakeholder Opinions: Diagnostics in Neurology - Predictive Biomarkers Expand Drug Revenues Product Image

Stakeholder Opinions: Diagnostics in Neurology - Predictive Biomarkers Expand Drug Revenues

  • Published: July 2008
  • 152 pages
  • Datamonitor

As advances in omics technologies enable the development of high value molecular diagnostics, neurological conditions represent an attractive target for diagnostic companies. In this report, the diseases are identified in which early detection with a biomarker could significantly benefit the patient, gain payer approval, and ultimately expand the pharmaceutical market.

Scope

- Neurological conditions covered: Alzheimers disease, Parkinsons disease, MS, epilepsy, migraine, insomnia, Huntingtons disease and ALS.

- Overview of key biomarkers in development for each condition (including genetics).

- Identification of key factors required for the commercial success of neurological diagnostic biomarkers.

- Analysis of potential drug revenue gains due to improved diagnostics in Alzheimers disease.

Highlights of this title

A battery or algorithm of tests for each disease is likely to be available within the next 10 years. This is already the case for multiple sclerosis, the most mature neurological diagnostic market, with both clinical, imaging and in vitro diagnostics incorporated in a clear algorithm.

Revenue gained from earlier use READ MORE >

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos